» Articles » PMID: 27143938

Metadherin Regulates Epithelial-mesenchymal Transition in Carcinoma

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2016 May 5
PMID 27143938
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Metadherin (MTDH) was first identified in primary human fetal astrocytes exposed to HIV-1 in 2002 and then recognized as an important oncogene mediating tumorigenesis, progression, invasiveness, and metastasis of carcinomas. Epithelial-mesenchymal transition (EMT) is a vital process in embryonic development, organ repair, and cancer progression. MTDH and EMT have also been proved to be related to the prognosis of patients with cancers. Recent studies reveal a relationship between MTDH overexpression and EMT in some malignancies. This review highlights the overexpression of MTDH and EMT in cancers and their correlations in clinical studies. Positive correlations have been established between MTDH and mesenchymal biomarkers, and negative correlations between MTDH and epithelial biomarkers have also been established. Furthermore, experiments reveal EMT regulated by MTDH, and some signal pathways have been established. Some anticancer drugs targeting MTDH and EMT are introduced in this review. Some perspectives concerning EMT regulation by MTDH are also presented in this review.

Citing Articles

Distinct molecular targets of ProEGCG from EGCG and superior inhibition of angiogenesis signaling pathways for treatment of endometriosis.

Hung S, Gaetani M, Li Y, Tan Z, Zheng X, Zhang R J Pharm Anal. 2024; 14(1):100-114.

PMID: 38352946 PMC: 10859541. DOI: 10.1016/j.jpha.2023.09.005.


MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown and in Preclinical Models.

Weidle U, Nopora A Cancer Genomics Proteomics. 2022; 19(2):113-129.

PMID: 35181582 PMC: 8865044. DOI: 10.21873/cgp.20308.


PRNCR1: a long non-coding RNA with a pivotal oncogenic role in cancer.

Bardhan A, Banerjee A, Basu K, Pal D, Ghosh A Hum Genet. 2021; 141(1):15-29.

PMID: 34727260 PMC: 8561087. DOI: 10.1007/s00439-021-02396-8.


Metadherin enhances vulnerability of cancer cells to ferroptosis.

Bi J, Yang S, Li L, Dai Q, Borcherding N, Wagner B Cell Death Dis. 2019; 10(10):682.

PMID: 31527591 PMC: 6746770. DOI: 10.1038/s41419-019-1897-2.


Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit.

Provvisiero D, Negri M, de Angelis C, Di Gennaro G, Patalano R, Simeoli C Sci Rep. 2019; 9(1):11695.

PMID: 31406139 PMC: 6690984. DOI: 10.1038/s41598-019-48081-9.


References
1.
Van T, Hanibuchi M, Goto H, Kuramoto T, Yukishige S, Kakiuchi S . SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model. Respirology. 2012; 17(6):984-90. DOI: 10.1111/j.1440-1843.2012.02193.x. View

2.
Wan L, Hu G, Wei Y, Yuan M, Bronson R, Yang Q . Genetic ablation of metadherin inhibits autochthonous prostate cancer progression and metastasis. Cancer Res. 2014; 74(18):5336-47. PMC: 4167565. DOI: 10.1158/0008-5472.CAN-14-1349. View

3.
Gong Z, Liu W, You N, Wang T, Wang X, Lu P . Prognostic significance of metadherin overexpression in hepatitis B virus-related hepatocellular carcinoma. Oncol Rep. 2012; 27(6):2073-9. DOI: 10.3892/or.2012.1749. View

4.
Song H, Li C, Li R, Geng J . Prognostic significance of AEG-1 expression in colorectal carcinoma. Int J Colorectal Dis. 2010; 25(10):1201-9. DOI: 10.1007/s00384-010-1009-3. View

5.
Zang L, Wu B, Lin Y, Wang J, Fu L, Tang Z . Research progress of ursolic acid's anti-tumor actions. Chin J Integr Med. 2013; 20(1):72-9. DOI: 10.1007/s11655-013-1541-4. View